Perceptive Advisors LLC, Director at Immatics N.V. (IMTX), bought 863,060 shares at $8.69 ($7.5M) on 2026-08-26, disclosed to the SEC on 2026-08-27.
Perceptive Advisors LLC purchased 863,060 shares of Immatics for $7.5M at $8.69, marking the largest insider purchase in the company's history. This significant capital commitment suggests the firm views the stock as undervalued relative to its clinical pipeline potential.
The stock is currently trading at a forward P/E of -4.53, indicating the market has priced in significant losses. The company reported a Q1 2026 loss of -19.05% on earnings and -38.95% on revenue, contributing to recent bearish sentiment.
Q1 2026 earnings on May 12, 2026, which saw a -19.05% earnings surprise and -38.95% revenue miss; the company is targeting a future product launch following completion of the Phase 3 SUPRAME trial for anzu-cel (IMA203); Zacks upgraded the stock to a Buy rating on May 6, 2026.
The stock has a short interest of 5.22% of the float, indicating a notable level of skepticism; the company reported a Q1 2026 revenue miss of -38.95%, highlighting execution risks in generating top-line growth.
Nothing distinguishes this filing.
| Filing → |
| ACRV | SELL | 2025-04-29 | $5.1M | — | Filing → |
| VRCA | BUY | 2023-12-26 | $3.6M | — | Filing → |
| ATXS | BUY | 2023-12-22 | $4.6M | — | Filing → |